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Abstract
A wealth of genetic associations for cardiovascular and metabolic phenotypes in humans has been accumulating over the
last decade, in particular a large number of loci derived from recent genome wide association studies (GWAS). True complex
disease-associated loci often exert modest effects, so their delineation currently requires integration of diverse phenotypic
data from large studies to ensure robust meta-analyses. We have designed a gene-centric 50 K single nucleotide
polymorphism (SNP) array to assess potentially relevant loci across a range of cardiovascular, metabolic and inflammatory
syndromes. The array utilizes a ‘‘cosmopolitan’’ tagging approach to capture the genetic diversity across ,2,000 loci in
populations represented in the HapMap and SeattleSNPs projects. The array content is informed by GWAS of vascular and
inflammatory disease, expression quantitative trait loci implicated in atherosclerosis, pathway based approaches and
comprehensive literature searching. The custom flexibility of the array platform facilitated interrogation of loci at differing
stringencies, according to a gene prioritization strategy that allows saturation of high priority loci with a greater density of
markers than the existing GWAS tools, particularly in African HapMap samples. We also demonstrate that the IBC array can
be used to complement GWAS, increasing coverage in high priority CVD-related loci across all major HapMap populations.
DNA from over 200,000 extensively phenotyped individuals will be genotyped with this array with a significant portion of
the generated data being released into the academic domain facilitating in silico replication attempts, analyses of rare
variants and cross-cohort meta-analyses in diverse populations. These datasets will also facilitate more robust secondary
analyses, such as explorations with alternative genetic models, epistasis and gene-environment interactions.
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Array-based genotyping technologies that have enabled
GWAS also permit flexibility in choosing the scope and density
of SNPs for candidate gene studies. For example, they allow
improved exploitation of recent deep resequencing data,
enabling more accurate capture of genetic diversity across
populations [15]. Such custom platforms, at scale, allow
inclusion of large numbers of plausible candidate loci with a
marginal increase in cost.
We describe here the design and implementation of a custom
50 K SNP genotyping array, primarily aimed at assaying SNPs
in candidate genes and pathways for cardiovascular, inflammatory and metabolic phenotypes. Design of this genotyping array
was led by investigators from the Institute of Translational
Medicine and Therapeutics (ITMAT), the Broad Institute and
by the National Heart Lung and Blood Institute (NHLBI)
supported Candidate-gene Association Resource (CARe) Consortium. The custom SNP array is hereafter referred to as the
‘‘IBC array’’ (ITMAT-Broad-CARe array). A consortium of
international academic and industrial partners have committed
to using the IBC array to genotype DNA from more than
200,000 individuals who have been extensively phenotyped for
risk factors and clinical evidence of vascular disease. The
objectives of forming this consortium were (i) to pool expertise
for selection of both loci and SNPs; (ii) to reduce costs by
producing a standardized genotyping platform; and (iii) to
facilitate cross cohort meta-analyses for a large set of SNPs in
high priority candidate loci. Here we formally describe the
resource and assess coverage of the genetic variants from
prioritized loci generated on the SNP panel with the HapMap

Introduction
Cardiovascular disease (CVD), the leading cause of death in
the developed world [1], has been shown to have significant
heritability [2–6]. The pattern of CVD in developed countries
has changed as the detection and management of risk factors
such as hypertension, hypercholesterolemia and predisposition to
thrombosis has coincided with a decline in the incidence of
myocardial infarction (MI) and stroke [7]. Efforts to discover
genetic determinants of complex disease have included analyses
of genetic variation, using SNPs, between populations of
individuals differing in incident or prevalent disease traits and/
or clinical events. However, many apparent associations have
not replicated for reasons including inadequate sample size,
imprecise or inaccurate phenotyping, insufficiently stringent
statistical thresholds, genuine heterogeneity of causality and
population stratification [8,9]. The International HapMap
Project [10], combined with advances in genotyping technologies, has led to the generation of multiple array-based SNP
genotyping products for GWAS. These developments enable
reasonably dense and unbiased global scans of the human
genome which have already identified novel loci associated with
CVD [11–14]. Despite the value of the GWAS approach, a
number of limitations exist, including cost and incomplete
coverage in the HapMap samples. GWAS also have relatively
low power to detect subtle, but potentially important effects, in
studies of ‘‘typical’’ sample sizes. For example, calculations of
the general power to detect a primary effect using an array with
.500 K SNPs are depicted in Figure 1.

Figure 1. Power to detect main effect with 550 K SNPs using various case control sizes & MAFs. Genome wide association power
calculated based on n unrelated cases and n unrelated controls. The disease model is assumed to be multiplicative with disease minor allele
frequency (MAF) = 0.05, 0.1, and 0.2, and the odds ratio = 1.2, 1.4, and 1.6. Significance is assessed at the 5% level using Bonferroni correction
assuming 550 K tests.
doi:10.1371/journal.pone.0003583.g001
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cell-types [20]; links to National Center for Biotechnology
Information (NCBI), Online Mendelian Inheritance in Man
(OMIM) and other reference databases; public resequencing
information; Jackson Lab Mouse (http://jaxmice.jax.org) and other
phenotypic data. A voting system built into this database facilitated
consensus amongst the consortium investigators for ranking genes
proposed for inclusion on the IBC array. Over 2,000 of these loci
were prioritized into three density criteria for tagging, as described
below, based on voting by the participating investigators.

populations. We also evaluate the coverage of the array with the
major GWAS products.

Methods
Processes for Loci selection
We used the following search string in PubMed ‘(genotype OR
snp OR allele* OR polymorphism OR variant) AND (coronary
OR heart OR myocardial OR cardiac OR ischemic OR
hypertension OR thrombosis) AND (linkage OR association OR
control OR randomized OR trial)’ covering publications from
1978 to May 2007, for version1 of the IBC array (IBCv1), and to
October 1st 2007 for the 2nd version of the IBC array (IBCv2). Key
information was collated including: PMID number, publishing
journal, size and population examined, loci and SNPs studied
(including the respective rs numbers, where retrievable) and
functional evidence. Over 2,400 published studies were systematically analyzed. Emphasis was placed on sample size, data quality
and strength of the described associations. Genes with known of
putative association with phenotypes for sleep, lung, and blood
diseases were also nominated. Input was also solicited directly
from investigators within and outside the consortium.
Several pathway-based tools were used to identify additional
biologically plausible candidate genes: Kyoto Encyclopedia of
Genes and Genomes (KEGG), [16]; Protein ANalysis THrough
Evolutionary Relationships (PANTHER), (www.pantherdb.org)
and BioCarta (www.biocarta.com). These tools were employed to
collate additional genes from key pathways including lipid
metabolism, thrombogenesis, circulation and gas exchange, insulin
resistance, metabolism, and inflammation, oxidative stress and
apoptosis.
Early access was provided to a number of unpublished mouse
atherosclerosis expression quantitative trait loci (eQTL) datasets.
Genes predicted to be causal for atherosclerotic lesion size in
genetic crosses of mice with differing susceptibility to atherosclerosis were identified [17] based on (i) the correlation between
transcript levels and lesion size, (ii) the overlap of expression and
atherosclerosis QTLs and (iii) the likelihood of a causal rather than
a dependent or reactive relationship based on Bayesian modeling.
Early access was provided to a number of key findings emerging
from five GWAS:
(i)
(ii)
(iii)
(iv)
(v)

Processes for SNP selection
Group 1 (n = 435 loci); genes and regions with a high likelihood
of functional significance, including established mediators of
vascular disease, loci derived from GWAS and those shown to
be associated with phenotypes of interest. Tag SNPs for these loci
were selected to capture known variation with MAF.0.02 and an
r2 of at least 0.8 in HapMap populations and SeattleSNPs where
available (for formal description, see Calculation of Coverage
section below).
Group 2 (n = 1,349 loci); candidate loci that are potentially
involved in phenotypes of interest or established loci that required
very large numbers of tagging SNPs. SNPs for these loci were
selected for MAFs.0.05 with an r2 of at least 0.5 in HapMap
populations and SeattleSNPs where available.
Group 3 (n = 232 loci); comprised mainly of the larger genes
(.100 kb) which were of lower interest a priori to the consortium
investigators. Only non-synonymous SNPs (nsSNPs) and known
functional variants of MAF.0.01 were captured for these loci.
Assays for specific SNPs of known or putative functionality and
those shown to be highly associated with vascular disease from
literature searching were directly ‘forced’ into the array content,
with the aim of facilitating more powerful downstream metaanalyses with previously published data. nsSNPs and known
functional variants of MAF.0.01 were selected where possible for
all genes of interest.
SNPs from Group 1 and 2 loci were first chosen using the
TAGGER software [21]. Assays for SNPs in Group 1 loci were
designed to be inclusive of the intronic, exonic, untranslated
regions (UTRs) and 5 kb of the proximal promoter regions derived
from NCBI build 35 with intronic, exonic and flanking UTRs
covered for the ‘Group 2’ loci. This approach generated a set of
tag SNPs and multimarker predictors that capture variation in the
four HapMap populations (CEU, Centre d’Etude du Polymorphisme Humain collection; CHB, Han Chinese in Beijing, China;
JPT, Japanese individuals from Tokyo, YRI, Yoruba from Ibadan,
Nigeria; HapMap Data release 21/phase II July 2006 on NCBI
build 35, dbSNP build 125). Where available, we also employed
SeattleSNPs (http://pga.gs.washington.edu) and Environmental
Genome Project (EGP), (http://egp.gs.washington.edu) resequencing data to identify additional tags, not represented in the
HapMap populations, using ldSelect [22]. We choose SNPs that
were observed at least twice in unrelated individuals.
SNPs were categorized by their assay design scores for the
Infinium genomic platform technology (Illumina, CA), based on a
theoretical algorithm and all previously attempted wet-lab
Infinium assays. In an attempt to reduce the proportion of failed
assays on the final product, we pre-filtered most SNPs for Infinium
design scores . = 0.6, finding appropriate proxies where possible.

The Wellcome Trust Case Control Consortium (WTCCC)
Hypertension study [18];
The WTCCC type 2 diabetes (T2D) study [12,18];
The WTCCC coronary artery disease study, [18];
Finland-United States Investigation of NIDDM Genetics
(FUSION) study [19]; and
The Broad-Novartis-Lund Diabetes Genetics Initiative
(DGI), [11].

A three-way meta-analysis of the WTCCC, Broad-NovartisLund and FUSION studies led to the generation of stronger T2D
candidate loci for inclusion on the custom array. We also included
SNPs reaching genome-wide significance from the WTCCC
Rheumatoid Arthritis, Crohn’s Disease and Type-1 Diabetes
studies [18].
Over 2,400 of the collated loci were placed on a database
(http://bmic.upenn.edu/cvdsnp) along with key information
displayed for each respective gene: the number of SNPs required
to tag the four HapMap representative populations at various
minor allele frequencies (MAFs) and r2 thresholds; SymAtlasH
expression profiling for over 70 specific human tissues and
PLoS ONE | www.plosone.org
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Informative SNP markers (AIMs) were included for African versus
European ancestry, and regional European (e.g. Northern versus
Southern) ancestral populations respectively to enable admixture
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independent samples with an effective sample size of up to
53,975 individuals [32].

mapping and adjustment for population stratification in studies
comprised of individuals from these ancestries. These SNPs were
based on panels generated previously [23,24], excluding SNPs
failing Hardy-Weinberg equilibrium (P.0.01). The AIMs panels
are listed within the IBC resource site (http://bmic.upenn.edu/
cvdsnp/updates/ancestry_informative_markers-ibc-v1.xls). The
incorporation of admixture and AIM panels enables admixture
mapping in African Americans and adjustment for population
stratification in African Americans and European Americans.
Genomic regions demonstrating ultra-high conservation across
species were identified as previously described [25]. Briefly,
regions were identified with at least 98% sequence similarity, with
a minimum length of 200 nucleotides within human-mouse-dog,
human-mouse-rat or human-chicken alignments. In addition,
conserved regions with sequence identity of at least 95% near the
Group 1, 2 and 3 loci were selected. All variants within these
regions (n = 1023 SNPs), as evident in at least one HapMap
population, were included on the IBC array.

Minor Allele Frequency Estimates
MAFs were assessed across the IBCv1 arrays in 6067 DNA
samples collated from three studies with five populations of self
described ethnicity, screened for cardiovascular traits; Caucasians
(n = 4244 European and n = 1054 US Caucasians); African
Americans (n = 384) and South Asians (n = 385). All samples
described were genotyped following approval by the relevant
institutional review boards. In each respective population, the minor
allele frequency for each SNP on the IBCv1 array was determined.
Histograms were generated with various allele frequency bins to
determine the distribution of allele frequencies in each population.

Calculation of Coverage
We used previously described methods [33] to calculate coverage
of HapMap SNPs. Briefly, pairwise r2 values were calculated using
the expectation algorithm [34] based on the genotypes from
HapMap release 22. Maximum r2 values were calculated for each
SNP list (HapMap release 22) with each SNP on the array being
tested. All pair-wise combinations were considered within 200 kb.
For chromosome X, only female individuals were used; otherwise, all
unrelated individuals were used.

Genotyping Platform Final Probe Selection
Assays for 49,234 SNPs were attempted using the Infinium
technology for IBCv1 [26,27] which became available to
consortium members in October 2007. Assays for an additional
4,050 SNPs were added to the initial content to comprise the
IBCv2 array to be released in the Summer of 2008. The additional
IBCv2 SNP content was mainly derived from the following:
(a)

(b)

(c)

(d)

(e)

Results

Proxy assays were attempted for a total of 596 SNPs that
failed during the manufacture of IBCv1. Some 1,143 of the
3,769 SNPs that failed assay conversion in manufacturing
were tagged by at least one passing SNP already on the array
(CEU r2. = 0.8). Suitable proxy assays for the remaining
2,626 SNPs were prioritized for supplementation based on
MAFs in the main HapMap populations and their respective
r2 value and Infinium design scores;
Additional literature scans for CVD genetic findings since
completion of IBCv1 using the same Pubmed search criteria
described earlier;
Combined GWAS analyses of the Diabetes Genetics
Initiative [11], the FUSION study [19] and the SardiNIA
study [28] of low-density lipoprotein (LDL), high-density
lipoprotein (HDL) and triglycerides. Analyses of these
datasets were followed by targeted replication analyses in
two independent efforts [29,30]. Common SNPs at 19 loci,
12 of which showed previous association (and are represented on IBCv1), were shown to be reproducibly associated
with levels of LDL, HDL and/or triglycerides. Two of the
seven novel loci described (P,561028 for each new locus)
are associated with LDL, two with HDL and five with
triglycerides;
Schadt and colleagues performed global expression profiling
on liver tissue and a GWAS on 427 Caucasian subjects.
Genotyping of .750,000 SNPs was performed and SNPs
were tested for association to each of the gene expression
traits. We included 130 SNPs with MAF.0.04 from this
study on IBCv2 that were identified as significantly
associated with at least one gene expression trait (p-value
for association ,1029; FDR,1%), [31];
Early access to ten novel loci relating to intermediate and
continuous CVD-related traits identified from an additional
meta-analyses of the FUSION [19], DGI [11] and
WTCCC-T2D [12] studies and were replicated in
PLoS ONE | www.plosone.org

Formal analysis of assay conversions
Assays for 49,234 SNPs were attempted during manufacturing
with 45,237 SNPs successfully passing the manufacturer’s criteria.
Reasons for failures included sub-optimal probe synthesis and
insufficient resolving of assay traces, potentially due to nearby
hidden SNPs or copy number variants (CNVs). Table 1 outlines
the type of genetic variants contained on IBCv1. Table S1 shows
the expected and observed conversion rates across the passing
SNPs. Over 1,300 more SNPs failed than had been predicted by
the theoretical conversion scores.
Table 1. Genetic variant types assayed on IBCv1.

Variant type

Number of SNPs
(% of total)

Exonic

4476 (9.9)

Variant Subtype
(number of SNPs)

Synonymous (825)
Non-synonymous (3280)
Other coding (371)
Intronic

29367 (64.9)

Untranslated Regions
(UTRs)

1602 (3.5)
59 UTR (162)
UTR (80)
39 UTR (1360)

Flanking UTRs

9792 (21.6)
Flanking 59 UTR (5966)
Flanking 39 UTR (3826)

Total

45237

Genetic variants covered on the IBC version 1 array categorized into exonix,
intronic, untranslated regions (UTRs) or flanking UTRs.
doi:10.1371/journal.pone.0003583.t001
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Figure 2. MAF distribution for IBCv1 assays across studies of Caucasians, African Americans and South Asians. Proportion of
polymorphic variants (as a % of total) are described on the y-axis with the x-axis illustrating bins of the minor allele frequencies (MAF) for six different
studies; Caucasian Study 1 (n = 2094 European); Caucasian Study 2 (n = 2150 European); Caucasian Study 3 (n = 1054 European American); African
American Study 1 (n = 254); African American Study 2 (n = 130) and South Asians (n = 385).
doi:10.1371/journal.pone.0003583.g002

(Figure 3). The average coverage for Group 1 loci is ,36.5 SNPs
per locus in IBCv1. The Illumina Human1M and Affymetrix 6.0
platform, for comparison, have an average of ,28.0 and ,17.4
SNPs respectively across the equivalent IBC loci. The average
number of SNPs observed for the Group 2 loci is ,16.3 SNPs
which is comparable with the current GWAS products.
The coverage of HapMap SNPs was evaluated for all Group 1
loci against the various GWAS products in the HapMap
individuals. The maximum r2 value was calculated between each
HapMap SNP in the region to a SNP in each respective product.
Figures 4 (a) through (f) shows the composite coverage of Group 1

Quality control
DNA samples from 117 HapMap individuals were genotyped
on the IBCv1. We have made these genotype files available for
the community (http://bmic.upenn.edu/cvdsnp/ updates/
hapmap_qc_samples-illumina.xls). 37,431 (82.7%) SNPs are
evident in HapMap. Approximately 99.5% concordance was
observed against respective HapMap data across the 117 samples
and 52 Mendelian inconsistencies were observed in 25 HapMap
trios (Table S2). All inconsistencies were attributable to a deleted
region from chromosome 1 in a proband which may be caused by
a bona fide de novo micro-deletion event or an artifact of the DNA
derived from the EBV-immortalised cell-lines. Complete reproducibility was observed across six replicate samples (Table S3).

Comparisons of MAFs of IBCv1 across DNA samples from
different populations
MAFs were assessed across the IBCv1 arrays in 6067 DNA
samples collated from three studies with five populations of self
described ethnicity, screened for cardiovascular traits; Caucasians
(n = 4244 European and n = 1054 US Caucasians); African
Americans (n = 384); and South Asians (n = 385). Some 1415
assays across the complete dataset were monomorphic. 2705 and
2566 assays were, respectively, monomorphic across self-described
Caucasians and African Americans. Figure 2 illustrates the
distribution of MAFs in the Caucasian, African American and
South Asian populations, respectively. The various bins for
MAFs.0.01 were comparable across all populations examined.
Significant variability was evident for variants with MAFs,0.005
which is expected, given the frequency of observations, the varying
number of individuals in each ethnic group studied and the natural
allele frequency differences of such variants across populations.

Figure 3. Average number of SNPs per Group 1 and 2 loci,
respectively, on IBCv1 compared with the major GWAS
products. IBCv1 Group 1 and Group 2 loci (n = 435 and 1,349) are
captured at MAF.0.02, r2 0.8 and MAF.0.05, r2 0.5 in HapMap
populations and SeattleSNPs, and illustrated in blue and red
respectively. IBCv1 refers to the ITMAT-Broad- CARE version1 array,
Illum650, Illum550 & Illum300 refer to Illumina HumanHap650Y,
HumanHap550 and HumanHap300 Infinium products containing
,660 K, ,550 K & ,317 K SNPs respectively and Affy 6.0 and Affy
5.0 refers to Affymetrix SNP array products containing ,907 K & 500 K
respectively.
doi:10.1371/journal.pone.0003583.g003

Comparison of IBCv1 with the current GWAS products
The average number of SNPs across the Group 1 and Group 2
loci of IBCv1 were compared with several GWAS products
PLoS ONE | www.plosone.org
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Figure 4. Coverage of IBCv1 versus GWAS products for Group1 loci in HapMap populations. Cumulative coverage (y axis) of the HapMap
22 release was assessed using Max r2 (6 axis), at an MAF cutoff of 0.02, in CEPH (CEU) (A), Chinese (CHB) plus Japanese (JPT), (B) and Yoruba (YRI)
HapMap individuals (C). Coverage was also assessed at an MAF cutoff of 0.05 in CEU (D), CHB+JPT (E), and YRI individuals (F). IBCv1 refers here to
version1 ITMAT-Broad-CARe array using 45,237 SNPs passed by the manufacture. ILMN_1M, ILMNHap550 and ILMNHap300 refer to Illumina’s
Human1M, HumanHap550 (555,352 SNPs) and HumanHap300 (317,503 SNPs) products, respectively. Affy_6.0 and Affy_5.0 refers to Affymetrix 6.0 &
Affymetrix 5.0 array products containing ,906,600 SNPs & 500,568 SNPs respectively.
doi:10.1371/journal.pone.0003583.g004

various sources including recent resequencing efforts; and (c) assay
directly specific SNPs of interest such as those derived from
previously published studies and known non-synonymous SNPs
with MAF.0.01. The IBC array reveals greater depth of coverage
than GWAS products with respect to information content and
haplotype diversity in the high priority regions. This is particularly
true of coverage for African HapMap representative samples. A
modest fraction of tagging SNPs from the Group 1 loci on the IBC
array are derived from SeattleSNPs analyses and were not assayed
directly in HapMap, thus it is likely that the cumulative coverage
of variation in these regions is actually underestimated in the
current results. It is worth noting that as HapMap was
predominantly used for the design of the IBC array (as well as
many of the commercial products), then additional densely
genotyped or sequenced populations, outside those covered in
the original HapMap, would be required for a completely
unbiased assessment of coverage.
Despite the recent reductions in price of whole genome SNP
arrays, GWAS still remain expensive endeavors and power to cost
issues are important factors in study design [35,36]. When a twostage GWAS design is employed, the need for custom genotyping
in the second stage can increase costs per individual to a
substantial fraction of the cost of the initial stage. GWAS are
limited because the cost prohibits acquisition of the sample size
needed to overcome the multiple testing problems inherent in
gene-gene analyses. Generating a consistent set of genotypes in
candidate genes within a large sample may in the short term
provide a better balance between sample size and number of
testable hypotheses than can be provided by the more expensive
and extensive GWAS, and will likely permit a better-powered
assessment of the contribution of epistasis to complex traits.
Furthermore the rational selection and greater density of coverage

loci from IBCv1 versus several GWAS products for CEU, YRI
and CHB+JPT HapMap individuals using MAF cutoffs of .0.02
and .0.05 across the spectrum of r2 thresholds. The coverage
using CEUs and CHB+JPT is comparable across all products,
although the IBCv1 coverage for YRI is greater. A number of the
GWAS products and the IBC array are strongly biased for
composition of HapMap SNPs and will obviously have skewed
coverage when directly compared. Over 20% of IBCv1 Group1
loci SNPs have not been assayed directly in HapMap with the
majority of these additional SNPs derived from SeattleSNPs and
the literature. Thus, the IBC array is likely to be more
representative of broader population allelic architecture.
The combined coverage of IBCv1 with a number of the GWAS
products was assessed for Group 1 loci. The coverage of the IBCv1
alone, with both of the 500 K SNP GWAS and with the one
million SNP array products across the Group 1 loci is illustrated in
Figure 5 under varying MAF thresholds across the HapMap
populations. The combined coverage using IBCv1 with both 1 M
SNP products is similar for Caucasians and Asian HapMap
samples. The increase in coverage is more pronounced in African
HapMap samples, reflecting the dense marker tagging for YRI in
the IBC array.

Discussion
We have produced a custom SNP array designed to capture
genetic variation in prioritized loci known or postulated to increase
risk of cardiovascular, metabolic and inflammatory diseases.
Custom SNP selection allowed us to: (a) ensure selective and
consistent coverage for a range of prioritized loci across multiple
ancestries, (b) provide additional representative coverage to
HapMap in loci of major interest, using SNP content from
PLoS ONE | www.plosone.org
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Figure 5. Combined coverage of IBCv1 with the 500 K and one million SNP products for Group1 loci in HapMap populations. For the
combined coverage of IBCv1 with the 500 K SNP products (A–F): coverage (y axis) was assessed using Max r2 (6axis), at an MAF cutoff of 0.02, for the
HapMap 22 release in CEPH (CEU) (A), Chinese (CHB) plus Japanese (JPT) (B), and Yoruba (YRI) HapMap individuals (C). Coverage was also assessed at
an MAF cutoff of 0.05 in CEU (D), CHB+JPT (E), and YRI individuals (F). For combined coverage with the one million SNP products (G–L): Coverage (y
axis) was also assessed using Max r2 (6axis), at an MAF cutoff of 0.02, for the HapMap 22 release in CEPH (CEU) (G), Chinese (CHB) plus Japanese (JPT)
(H), and Yoruba (YRI) HapMap individuals (I) and coverage with an MAF cutoff of 0.05 in CEU (J), CHB+JPT (K), and YRI individuals (L). IBCv1 refers
here to the version1 ITMAT-Broad-CARe array using 45,237 SNPs that passed manufacturers criteria. Affy_5.0 refers to the Affymetrix 5.0 array and
ILMN_HapMap550 refers to the Infinium 550 K HumanHap array which contains 500,568 and 555,352 SNPs respectively. Affy_6.0 refers to the
Affymetrix 6.0 array and ILMN_1M refers to the Illumina Infinium one million SNP array containing ,906,600 and ,1,050,000 SNPs respectively.
doi:10.1371/journal.pone.0003583.g005

The HapMap project had a bias towards discovery and
genotyping of variants with MAFs.0.05, but over 40% of SNPs
were observed to have MAFs,0.05 [10] and the ENCyclopedia
Of DNA Elements (ENCODE) project indicates ,60% of SNPs
have MAFs,0.05 [37]. Many case-control association studies of
complex diseases have tended to use MAFs.0.05 due to the
power constraints of typical samples sizes. Gorlov and colleagues
recently postulated that SNPs that are potentially deleterious are

in these prioritized loci in the IBC array biases towards detection of
disease causing loci, that complements the discovery nature of an
unbiased GWAS strategy. As the IBC array is available as a standard
tool to the community, the cost is greatly reduced with respect to
custom genotyping. The IBC array can clearly be used in
conjunction with GWAS products to increase coverage in the high
priority regions, permitting greater exploration of gene-interactions
and other secondary analyses for the collated high priority loci.
PLoS ONE | www.plosone.org
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subjected to weak purifying selection and may represent significant
contributors to genetic components of common disease [38].
Indeed potentially damaging nsSNPs are skewed toward rarer
distribution in the HapMap project, ENCODE and SeattleSNPs.
In a recent study comparing the Illumina 14.5 K nsSNP array
with GWAS tools (Affy 5.0, Illumina HumanHap300 and
HumanHap550), Evans and colleagues found that the GWAS
products failed to capture most of the rare variants present on the
nsSNP platform [39]. The major nsSNP studies attempted thus far
have had modest sample sizes of ,1500 cases and controls [40].
All nsSNPs.MAF 0.01 have been targeted in the design of the
IBC array using information from both HapMap and SeattleSNPs
and have tagged to MAFs.0.02 for a large number of key loci
related to vascular diseases. Analyses of such lower frequency
variants will be facilitated by the formation of an international
consortium of investigators committed to using this platform. This
will permit collaborative meta-analyses across a broad range of
phenotypes. The CARe Consortium, for example, will make their
IBCv2 genotype data (n,50,000 samples) and most related
phenotypic data available to the academic community.
The IBC array is one of the first disease-specific custom arrays
with highly focused content to be used on a large scale. We
anticipate further generations of the IBC array and that future
aggregation of large cohorts and studies with similar disease traits
will become commonplace, affording significant cost reductions
and increased power to detect effects of modest size.

errors across the IBC version1 array using 25 HapMap individuals,
where NA number denotes the official HapMap identifier.
Found at: doi:10.1371/journal.pone.0003583.s002 (0.08 MB
DOC)
Observed replicate consistency using six HapMap
individuals. Observed IBC version1 array genotyping errors for six
replicate HapMap samples, where NA number denotes the official
HapMap identifier.
Found at: doi:10.1371/journal.pone.0003583.s003 (0.05 MB
DOC)

Table S3

Acknowledgments
The CARe Consortium wishes to acknowledge the support of the National
Heart, Lung, and Blood Institute and the contributions of the research
institutions, study investigators, field staff and study participants in creating
this resource for biomedical research. The following nine parent studies
have contributed parent study data, ancillary study data, and DNA samples
through the Massachusetts Institute of Technology - Broad Institute to
create this genotype/phenotype database for wide dissemination to the
biomedical research community: the Atherosclerosis Risk in Communities
(ARIC) study, the Cardiovascular Health Study (CHS), the Cleveland
Family Study (CFS), the Cooperative Study of Sickle Cell Disease
(CSSCD), the Coronary Artery Risk Development in Young Adults
(CARDIA) study, the Framingham Heart Study (FHS), the Jackson Heart
Study (JHS), the Multi-Ethnic Study of Atherosclerosis (MESA), and the
Sleep Heart Health Study (SHHS). The authors also acknowledge key
contributions from the WTCCC, FUSION and DGI studies. We thank
Mary Leonard for preparation of figures and Gonzalo Abecasis for
contributions of loci towards IBCv2.

Supporting Information
Table S1 Bins of SNPs with observed and expected Infinium
conversion scores The distribution of SNPs binned according to
Infinium score from 0.1 to 1 where a score of 0.8 indicates an 80%
likelihood for conversion to a successful assay, 1.0 indicates an
assay has ,100% theoretical score etc. A value of 1.1 indicates
that an Infinium assay for SNPs has previously been successful in
manufacture and analyses. Percentages are indicated in brackets.
Found at: doi:10.1371/journal.pone.0003583.s001 (0.05 MB
DOC)

Author Contributions
Conceived and designed the experiments: BJK ST SSM TB TSP LG JCB
DNF GJP PdB MF CWKC RRF EB JGW MIM SG MR JCE DAN JH.
Performed the experiments: BJK MH SDB AM EF CEK WK HH SSA
JCE. Analyzed the data: BJK ST SSM TB JTG LG JCB SFAG HC MH
WK HH JCE DAN JH. Contributed reagents/materials/analysis tools:
BJK ST SSM TB LG HC MH GJP SA YG ML SD PdB SDB AM ACE
KDT XG SSW TS LCG MB ASH AH NP CWKC WHO ALP PM MC
TAD DR ASW TC NJS AJL EES WK MIM SK HH SSA MR JCE DAN
DJR JH. Wrote the paper: BJK ST TSP SFAG DNF GJP YG EB JGW
MIM HH JCE DAN DJR JH GAF.

Table S2 Observed IBCv1 Mendelian consistency across 25
HapMap trios. Observed Parent-Parent-Child (PPC) heritability

References
1. Danesh J, Saracci R, Berglund G, Feskens E, Overvad K, et al. (2007) EPICHeart: the cardiovascular component of a prospective study of nutritional,
lifestyle and biological factors in 520,000 middle-aged participants from 10
European countries. Eur J Epidemiol 22: 129–141.
2. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U (1994) Genetic
susceptibility to death from coronary heart disease in a study of twins.
N Engl J Med 330: 1041–1046.
3. Lusis AJ, Mar R, Pajukanta P (2004) Genetics of atherosclerosis. Annu Rev
Genomics Hum Genet 5: 189–218.
4. Pilia G, Chen WM, Scuteri A, Orru M, Albai G, et al. (2006) Heritability of
cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet 2: e132.
5. Mayer B, Erdmann J, Schunkert H (2007) Genetics and heritability of coronary
artery disease and myocardial infarction. Clin Res Cardiol 96: 1–7.
6. Kullo IJ, Ding K (2007) Mechanisms of disease: The genetic basis of coronary
heart disease. Nat Clin Pract Cardiovasc Med 4: 558–569.
7. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006) Global and
regional burden of disease and risk factors, 2001: systematic analysis of
population health data. Lancet 367: 1747–1757.
8. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive
review of genetic association studies. Genet Med 4: 45–61.
9. Morgan TM, Krumholz HM, Lifton RP, Spertus JA (2007) Nonvalidation of
reported genetic risk factors for acute coronary syndrome in a large-scale
replication study. JAMA 297: 1551–1561.
10. International HapMap Consortium (2005) A haplotype map of the human
genome. Nature 437: 1299–1320.
11. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, et al. (2007)
Genome-wide association analysis identifies loci for type 2 diabetes and
triglyceride levels. Science 316: 1331–1336.

PLoS ONE | www.plosone.org

12. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, et al. (2007)
Replication of genome-wide association signals in UK samples reveals risk loci
for type 2 diabetes. Science 316: 1336–1341.
13. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, et al. (2007) A
common allele on chromosome 9 associated with coronary heart disease. Science
316: 1488–1491.
14. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, et al. (2007)
Genomewide association analysis of coronary artery disease. N Engl J Med 357:
443–453.
15. Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, et al.
(2007) Population-based resequencing of ANGPTL4 uncovers variations that
reduce triglycerides and increase HDL. Nat Genet 39: 513–6.
16. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes.
Nucleic Acids Res 28: 27–30.
17. Wang SS, Schadt EE, Wang H, Wang X, Ingram-Drake L, et al. (2007)
Identification of pathways for atherosclerosis in mice: integration of quantitative
trait locus analysis and global gene expression data. Circ Res 101: e11–30.
18. Wellcome Trust Case Control Consortium (2007) Genome-wide association
study of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature 447: 661–678.
19. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, et al. (2007) A genomewide association study of type 2 diabetes in Finns detects multiple susceptibility
variants. Science 316: 1341–1345.
20. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, et al. (2002) Large-scale
analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A 99:
4465–4470.
21. de Bakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ, et al. (2005) Efficiency
and power in genetic association studies. Nat Genet 37: 1217–1223.

8

October 2008 | Volume 3 | Issue 10 | e3583

IBC Array Tech Spec Paper

31. Schadt EE, Molony C, Chudin E, Hao K, Yang X, et al. (2008) Mapping the
genetic architecture of gene expression in human liver. PLoS Biol 6(5): e107.
32. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, et al. (2008) Metaanalysis of genome-wide association data and large-scale replication identifies
additional susceptibility loci for type 2 diabetes. Nat Genet Epub Mar 30.
33. Eberle MA, Ng PC, Kuhn K, Zhou L, Peiffer DA, et al. (2007) Power to detect
risk alleles using genome-wide tag SNP panels. PLoS Genet 10: 1827–37.
34. Hill WG, Robertson A (1968) The effects of inbreeding at loci with heterozygote
advantage. Genetics 60: 615–628.
35. Skol AD, Scott LJ, Abecasis GR, Boehnke M (2007) Optimal designs for twostage genome-wide association studies. Genet Epidemiol 31: 776–788.
36. Anderson CA, Pettersson FH, Barrett JC, Zhuang JJ, Ragoussis J, et al. (2008)
Evaluating the effects of imputation on the power, coverage, and cost efficiency
of genome-wide SNP platforms. Am J Hum Genet 1: 112–9.
37. ENCODE Project Consortium (2004) The ENCODE (ENCyclopedia Of DNA
Elements) Project. Science 306: 636–640.
38. Gorlov IP, Gorlova OY, Sunyaev SR, Spitz MR, Amos CI (2008) Shifting
paradigm of association studies: value of rare single-nucleotide polymorphisms.
Am J Hum Genet 82: 100–112.
39. Evans DM, Barrett JC, Cardon LR (2008) To what extent do scans of nonsynonymous SNPs complement denser genome-wide association studies?
Eur J Hum Genet 6: 718–23.
40. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, et al. (2007)
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies
autoimmunity variants. Nat Genet 39: 1329–1337.

22. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, et al. (2004) Selecting a
maximally informative set of single-nucleotide polymorphisms for association
analyses using linkage disequilibrium. Am J Hum Genet 74: 106–120.
23. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, et al. (2007)
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat
Genet 39: 638–644.
24. Price AL, Butler J, Patterson N, Capelli C, Vincenzo L, et al. (2008) Discerning
the Ancestry of European Americans in Genetic Association Studies. PLoS
Genet 1: e236.
25. Derti A, Roth FP, Church GM, Wu CT (2006) Mammalian ultraconserved
elements are strongly depleted among segmental duplications and copy number
variants. Nat Genet 10: 1216–20.
26. Gunderson KL, Steemers FJ, Lee G, Mendoza LG, Chee MS (2005) A genomewide scalable SNP genotyping assay using microarray technology. Nat Genet 37:
549–554.
27. Steemers FJ, Chang W, Lee G, Barker DL, Shen R, et al. (2006) Whole-genome
genotyping with the single-base extension assay. Nat Methods 3: 31–33.
28. Pilia G, Chen WM, Scuteri A, Orru M, Albai G, et al. (2006) Heritability of
cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet 2: e132.
29. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, et al. (2008) Six new
loci associated with blood low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol or triglycerides in humans. Nat Genet 40: 189–197.
30. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, et al. (2008) Newly
identified loci that influence lipid concentrations and risk of coronary artery
disease. Nat Genet 40: 161–169.

PLoS ONE | www.plosone.org

9

October 2008 | Volume 3 | Issue 10 | e3583

